This Trial is Conducted Globally. The Aim of This Trial is to Compare the Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Insulin degludec/insulin aspart (Primary) ; Insulin aspart; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Novo Nordisk
- 07 Dec 2017 This trial has been completed in Czech Republic.
- 10 Jun 2017 Biomarkers information updated
- 16 Mar 2017 Status changed from recruiting to active, no longer recruiting.